NanoVibronix Renews Distribution Agreement with Ultra Pain Products Inc., Secures $12 Million Minimum Purchase Commitment

NanoVibronix, a medical device company listed on the NASDAQ exchange under the ticker symbol NAOV, announced on December 11, 2024, the extension of its exclusive distribution agreement with Ultra Pain Products Inc. for its PainShield product for an additional five years. This renewal signifies a significant milestone for the company, underscoring a continued partnership that aims to bring advanced therapeutic solutions to patients in need.

Brian Murphy, the CEO of NanoVibronix, expressed enthusiasm about the extended collaboration, stating, “We are thrilled to extend our partnership with Ultra Pain Products for another five years and secure a minimum purchase commitment of our products valued at $12 million. UPPI’s impressive growth, transition into manufacturing, and dedication to innovation align perfectly with our values and goals.”

The decision to renew the distribution agreement was influenced by Ultra Pain Products’ notable growth over the past four years, positioning it as a key player in the non-opioid pain management and injury recovery industry. The continued collaboration between NanoVibronix and UPPI highlights a shared commitment to providing effective and accessible solutions to patients.

Ari Alayev, President of Ultra Pain Products, emphasized the importance of the agreement, stating, “We are honored to continue our exclusive distribution agreement with NanoVibronix. We view our partnership as a collaboration that strengthens each organization’s impact in the market. This renewal is a testament to our shared vision and the mutual trust we have built over the past four years.”

This renewed agreement reflects the mutual dedication of both companies to advancing non-opioid treatment options in the U.S. market. It signifies a strategic alignment in supporting injury recovery and enhancing patient care through innovative technologies.

NanoVibronix, headquartered in Tyler, Texas, with research and development operations in Nesher, Israel, specializes in medical devices utilizing its patented low-intensity surface acoustic wave (SAW) technology. The company’s flagship products, PainShield® and UroShield®, offer portable and effective solutions for various medical applications, including pain relief and bacterial colonization disruption.

Investors and stakeholders in NanoVibronix are encouraged to review the company’s filings with the Securities and Exchange Commission (SEC) for additional information on the risks and factors affecting the company’s forward-looking statements. The company remains committed to delivering value to its shareholders through strategic partnerships and innovative medical solutions.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read NanoVibronix’s 8K filing here.

NanoVibronix Company Profile

NanoVibronix, Inc, through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.